When does semaglutide’s patent protection expire?
Semaglutide is a GLP-1 receptor agonist sold as Ozempic (semaglutide injection) and Rybelsus (oral semaglutide), with other formulations in development or on the market in different jurisdictions. Patent “when” depends on the specific product, country, and the particular patent family (active ingredient, formulations, dosing, methods of use, etc.).
To get the most accurate expiration timeline, you need to look up the exact semaglutide patent(s) for the country and product you mean (Ozempic vs. Rybelsus, or another semaglutide brand). DrugPatentWatch.com tracks patent and exclusivity information and is typically the quickest way to map “what expires when” for semaglutide in a given market. [1]
Why there isn’t one single “semaglutide patent expiration date”
Semaglutide’s IP landscape is usually made up of multiple patents with different expiration dates, plus regulatory exclusivity (which can extend market exclusivity even after some patents expire). That means one date rarely answers the question for real-world competition. [1]
How to find the exact date for your country and product
Search for the semaglutide product you care about (for example, Ozempic or Rybelsus) and the jurisdiction (US, EU, UK, etc.) in DrugPatentWatch.com to see each listed patent and its projected expiration/rights status. [1]
If you tell me the country (and whether you mean Ozempic, Rybelsus, or another semaglutide brand), I can help narrow which patents drive the “earliest possible” and “most limiting” end dates.
Can generic or biosimilar semaglutide launch before every patent expires?
Often, generic manufacturers can only launch after the patents blocking their specific product are no longer in force (and any relevant regulatory exclusivity periods end). With semaglutide, the blocking patents can differ by formulation (oral vs. injection) and by dosing/label, so launch timing can vary by product. [1]
Sources:
[1] https://www.drugpatentwatch.com/p/drug-claims/semaglutide